Clinical trials
Terminated Kidney Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
86 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 5 |
| 2005 | 5 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 10 |
| 2009 | 6 |
| 2010 | 7 |
| 2011 | 4 |
| 2012 | 5 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 86 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 16 |
| Masonic Cancer Center, University of Minnesota | 4 |
| Celldex Therapeutics | 3 |
| University of Wisconsin, Madison | 3 |
| Agenus Inc. | 2 |
| Argos Therapeutics | 2 |
| M.D. Anderson Cancer Center | 2 |
| Medical University of South Carolina | 2 |
| National Institutes of Health Clinical Center (CC) | 2 |
| NiKang Therapeutics, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kidney Neoplasms | 86 |
| Carcinoma, Renal Cell | 57 |
| Melanoma | 17 |
| Neoplasm Metastasis | 12 |
| Lung Neoplasms | 11 |
| Neoplasms | 10 |
| Breast Neoplasms | 9 |
| Ovarian Neoplasms | 9 |
| Sarcoma | 9 |
| Liver Neoplasms | 7 |
Trials
Showing 1 to 25 of 86. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.